4.7 Article

The role of chemotherapy at the end of life: When is enough, enough?

Journal

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Volume 299, Issue 22, Pages 2667-E1

Publisher

AMER MEDICAL ASSOC
DOI: 10.1001/jama.299.22.2667

Keywords

-

Funding

  1. NCI NIH HHS [R01CA116227-01, R01 CA116227] Funding Source: Medline
  2. NLM NIH HHS [1G08LM009525-01, G08 LM009525, G08 LM009525-01] Funding Source: Medline

Ask authors/readers for more resources

Patients face difficult decisions about chemotherapy near the end of life. Such treatment might prolong survival or reduce symptoms but cause adverse effects, prevent the patient from engaging in meaningful life review and preparing for death, and preclude entry into hospice. Palliative care and oncology clinicians should be logical partners in caring for patients with serious cancers for which symptom control, medically appropriate goal setting, and communication are paramount, but some studies have shown limited cooperation. We illustrate how clinicians involved in palliative care and oncology can more effectively work together with the story of Mr L, a previously healthy 56- year- old man, who wanted to survive his lung cancer at all costs. He lived 14 months with 3 types of chemotherapy, received chemotherapy just 6 days before his death, and resisted entering hospice until his prognosis and options were explicitly communicated. Approaches to communication about prognosis and treatment options and questions that patients may want to ask are discussed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available